Premium
The discovery of antiviral agents: Ten different compounds, ten different stories
Author(s) -
De Clercq Erik
Publication year - 2008
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.20128
Subject(s) - adefovir , cidofovir , valaciclovir , tenofovir , stavudine , famciclovir , lamivudine , human immunodeficiency virus (hiv) , virology , pharmacology , chemistry , medicine , virus , hepatitis b virus , viral disease , herpesviridae
This review article, while autobiographical to some extent, describes the discovery of ten (classes of) antiviral compounds that have made (or just did not make) it to the market for the therapy of viral infections, but each in its own way influenced the landscape of our dealing with virus infections: (i) valaciclovir, (ii) BVDU, (iii) DHPA, (iv) cidofovir, (v) adefovir, (vi) tenofovir, (vii) stavudine, (viii) HEPT, (ix) TIBO, and (x) AMD3100. Successful drug development, as is certainly true for antiviral drugs and exemplified for the acyclic nucleoside phosphonates cidofovir, adefovir and tenofovir, requires patience and perseverance, and a close continuous and dedicated interaction between Chemistry, Biology/Medicine and Industry. © 2008 Wiley Periodicals, Inc. Med Res Rev, 28, No. 6, 929–953, 2008